This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Arnold M, Holterhues C, Hollestein LM, Coebergh JWW, Nijsten T, Pukkala E, et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol JEADV 2014; 28: 1170-8. 10.1111/jdv.12236ArnoldMHolterhuesCHollesteinLMCoeberghJWWNijstenTPukkalaETrends in incidence and predictions of cutaneous melanoma across Europe up to 2015J Eur Acad Dermatol Venereol JEADV2014281170810.1111/jdv.12236Open DOISearch in Google Scholar
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016. Eur J Cancer 2016; 63: 201-17. 10.1016/j.ejca.2016.05.005GarbeCPerisKHauschildASaiagPMiddletonMBastholtLDiagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016Eur J Cancer2016632011710.1016/j.ejca.2016.05.005Open DOISearch in Google Scholar
Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-76. 10.1056/NEJMoa1408868LarkinJAsciertoPADrénoBAtkinsonVLiszkayGMaioMCombined vemurafenib and cobimetinib in BRAF-mutated melanomaN Engl J Med201437118677610.1056/NEJMoa1408868Open DOISearch in Google Scholar
Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26: v126-32. 10.1093/annonc/mdv297DummerRHauschildALindenblattNPentheroudakisGKeilholzU.Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201526v1263210.1093/an-nonc/mdv297Open DOISearch in Google Scholar
Ascierto PA, Kirkwood JM, Grob J-J, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J Transl Med 2012; 10: 85. 10.1186/1479-5876-10-85AsciertoPAKirkwoodJMGrobJ-JSimeoneEGrimaldiAMMaioMThe role of BRAF V600 mutation in melanomaJ Transl Med2012108510.1186/1479-5876-10-85Open DOISearch in Google Scholar
Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 2013; 14: e60-9. 10.1016/S1470-2045(12)70539-9JangSAtkinsMB.Which drug, and when, for patients with BRAF-mutant melanoma?Lancet Oncol201314e60910.1016/S1470-2045(12)70539-9Open DOISearch in Google Scholar
Urner-Bloch U, Urner M, Jaberg-Bentele N, Frauchiger AL, Dummer R, Goldinger SM. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects. Eur J Cancer 2016; 65: 130-8. 10.1016/j.ejca.2016.06.018Urner-BlochUUrnerMJaberg-BenteleNFrauchigerALDummerRGoldingerSM.MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effectsEur J Cancer201665130810.1016/j.ejca.2016.06.018Open DOISearch in Google Scholar
Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM, et al. Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy. Ophthalmology 2017. 10.1016/j.ophtha.2017.05.038. [Epub ahead of print]FrancisJHHabibLAAbramsonDHYannuzziLAHeinemannMGounderMMClinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathyOphthalmology201710.1016/j.ophtha.2017.05.038[Epub ahead of print]Open DOISearch in Google Scholar
Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol 2014; 158: 831-837.e2. 10.1016/j.ajo.2014.07.003ChoeCHMcArthurGACaroIKempenJHAmaravadiRK.Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenibAm J Ophthalmol2014158831837e210.1016/j.ajo.2014.07.003Open DOISearch in Google Scholar
Dréno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol 2017; 28: 1137-44. 10.1093/annonc/mdx040DrénoBRibasALarkinJAsciertoPAHauschildAThomasLIncidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM studyAnn Oncol20172811374410.1093/annonc/mdx040Open DOISearch in Google Scholar
de la Cruz-Merino L, Di Guardo L, Grob J-J, Venosa A, Larkin J, McArthur GA, et al. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. J Transl Med 2017; 15: 146. 10.1186/s12967-017-1246-0de la Cruz-MerinoLDi GuardoLGrobJ-JVenosaALarkinJMcArthurGAClinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM studyJ Transl Med20171514610.1186/s12967-017-1246-0Open DOISearch in Google Scholar
Alves C, Ribeiro I, Penedones A, Mendes D, Batel Marques F. Risk of ophthalmic adverse effects in patients treated with MEK inhibitors: A systematic review and meta-analysis. Ophthalmic Res 2017; 57: 60-9. 10.1159/000446845AlvesCRibeiroIPenedonesAMendesDBatel MarquesF.Risk of ophthalmic adverse effects in patients treated with MEK inhibitors: A systematic review and meta-analysisOphthalmic Res20175760910.1159/000446845Open DOISearch in Google Scholar
Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 2015; 7: 122-36. 10.1177/1758834014566428WelshSJCorriePG.Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanomaTher Adv Med Oncol201571223610.1177/1758834014566428Open DOISearch in Google Scholar
Schoenberger SD, Kim SJ. Bilateral multifocal central serous-like chorioretinopathy due to MEK inhibition for metastatic cutaneous melanoma. Case Rep Ophthalmol Med 2013; 2013: 1-3. 10.1155/2013/673796SchoenbergerSDKimSJ.Bilateral multifocal central serous-like chorioretinopathy due to MEK inhibition for metastatic cutaneous melanomaCase Rep Ophthalmol Med201320131310.1155/2013/673796Open DOISearch in Google Scholar
Michalarea V, de Miguel Luken MJ, Diamantis N, Garg A, Maubon L, Yap TA, et al. Ocular toxicity with MEK inhibitors in phase I trials: A single centre experience across six clinical trials. J Clin Oncol 2015; 33: 11090-90. 10.1200/jco.2015.33.15_suppl.11090MichalareaVde Miguel LukenMJDiamantisNGargAMaubonLYapTAOcular toxicity with MEK inhibitors in phase I trials: A single centre experience across six clinical trialsJ Clin Oncol201533110909010.1200/jco.2015.33.15_suppl.11090Open DOISearch in Google Scholar
van Dijk EHC, van Herpen CML, Marinkovic M, Haanen JBAG, Amundson D, Luyten GPM, et al. Serous retinopathy associated with mitogen-activated protein kinase inhibition (Binimetinib) for metastatic cutaneous and uveal melanoma. Ophthalmology 2015; 122: 1907-16. 10.1016/j.ophtha.2015.05.027van DijkEHCvan HerpenCMLMarinkovicMHaanenJBAGAmundsonDLuytenGPMSerous retinopathy associated with mitogen-activated protein kinase inhibition (Binimetinib) for metastatic cutaneous and uveal melanomaOphthalmology201512219071610.1016/j.ophtha.2015.05.027Open DOISearch in Google Scholar
Weber ML, Liang MC, Flaherty KT, Heier JS. Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancer. JAMA Ophthalmol 2016; 134: 855-62. 10.1001/jamaophthalmol.2016.0090WeberMLLiangMCFlahertyKTHeierJS.Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancerJAMA Ophthalmol20161348556210.1001/jamaophthalmol.2016.0090Open DOISearch in Google Scholar
Stjepanovic N, Velazquez-Martin JP, Bedard PL. Ocular toxicities of MEK inhibitors and other targeted therapies. Ann Oncol 2016; 27: 998-1005. 10.1093/annonc/mdw100StjepanovicNVelazquez-MartinJPBedardPL.Ocular toxicities of MEK inhibitors and other targeted therapiesAnn Oncol201627998100510.1093/annonc/mdw100Open DOISearch in Google Scholar
Jiang Q, Cao C, Lu S, Kivlin R, Wallin B, Chu W, et al. MEK/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med 2009; 23: 771-7.JiangQCaoCLuSKivlinRWallinBChuWMEK/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cellsInt J Mol Med200923771710.3892/ijmm_00000191Search in Google Scholar
Huang W, Yang AH, Matsumoto D, Collette W, Marroquin L, Ko M, et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol 2009; 25: 519-30. 10.1089/jop.2009.0060HuangWYangAHMatsumotoDColletteWMarroquinLKoMPD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusionJ Ocul Pharmacol2009255193010.1089/jop.2009.0060Open DOISearch in Google Scholar
Runkle EA, Antonetti DA. The blood-retinal barrier: Structure and functional significance. In: Nag S, editor. Blood-Brain Neural Barriers, vol. 686, Totowa, NJ: Humana Press; 2011. p. 133-48.RunkleEAAntonettiDA.The blood-retinal barrier: Structure and functional significanceNagSBlood-Brain Neural Barriers686Totowa, NJHumana Press20111334810.1007/978-1-60761-938-3_5Search in Google Scholar
Niro A, Strippoli S, Alessio G, Sborgia L, Recchimurzo N, Guida M. Ocular toxicity in metastatic melanoma patients treated with mitogen-activated protein kinase inhibitors: a case series. Am J Ophthalmol 2015; 160: 959-67. e1. 10.1016/j.ajo.2015.07.035NiroAStrippoliSAlessioGSborgiaLRecchimurzoNGuidaM.Ocular toxicity in metastatic melanoma patients treated with mitogen-activated protein kinase inhibitors: a case seriesAm J Ophthalmol201516095967 e110.1016/j.ajo.2015.07.035Open DOISearch in Google Scholar
Guedj M, Quéant A, Funck-Brentano E, Kramkimel N, Lellouch J, Monnet D, et al. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib. JAMA Ophthalmol 2014; 132: 1421-5. 10.1001/jamaophthalmol.2014.3024GuedjMQuéantAFunck-BrentanoEKramkimelNLellouchJMonnetDUveitis in patients with late-stage cutaneous melanoma treated with vemurafenibJAMA Ophthalmol20141321421510.1001/jamaophthalmol.2014.3024Open DOISearch in Google Scholar
